Frequent Fas gene mutations in testicular germ cell tumors

American Journal of Pathology

Volumn 161, Issue 2, 2002, Pages 635-641

  Takayama, Hitoshi ^a   Takakuwa, Tetsuya ^a   Tsujimoto, Yuichi ^a   Tani, Yoichi ^b   Nonomura, Norio ^a   Okuyama, Akihiko ^a   Nagata, Shigekazu ^a   Aozasa, Katsuyuki ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b DAKO Japan ^*  (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; FAS ANTIBODY; FAS ANTIGEN; FAS LIGAND;

APOPTOSIS; ARTICLE; CELL DEATH; CHORIOCARCINOMA; CHROMOSOME MICRODISSECTION; CLINICAL ARTICLE; CONTROLLED STUDY; EMBRYONAL CARCINOMA; FAS GENE; GENE MUTATION; GENETIC RESISTANCE; GENETIC TRANSFECTION; GERM CELL TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MALE; MISSENSE MUTATION; PATHOGENESIS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; SEMINOMA; SIGNAL TRANSDUCTION; TERATOMA; TESTIS CELL; YOLK SAC TUMOR;

EID: 0036969387     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64219-8     Document Type: Article

References (27)

1. Suda T, Takahashi T, Goldstein P, Nagata S: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993, 75:1169-1178
2. Nagata S: Apoptosis by death factor. Cell 1997, 88:355-365
3. Itoh N, Nagata S: A novel protein domain required for apoptosis. J Biol Chem 1993, 268:10932-10937
4. Watanabe-Fukunaga R, Brannan C, Itoh N, Yonehara S, Copeland NG, Jenkins NA, Nagata S: The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol 1992, 148:1274-1279
5. Leithäuser F, Dhein J, Mechtersheimer G, Koretz K, Bründerlein S, Henne C, Schmidt A, Debatin KM, Krammer PH, Möller P: Constitutive and induced expression of APO-1, a new member of the new growth factor/tumor necrosis receptor superfamily, in normal and neoplastic cells. Lab Invest 1993, 69:415-429
6. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC: A role for CD95 ligand in preventing graft rejection. Nature 1995, 377: 630-632
7. Lee J, Richburg JH, Younkin SC, Boekelheide K: The Fas system is a key regulator of germ cell apoptosis in the testis. Endocrinology 1997, 138:2081-2088
8. Pentikäinen V, Erkkilä K, Dunkel L: Fas regulates germ cell apoptosis in the human testis in vitro. Am J Physiol 1999, 276:E310-E316
9. Landowski TH, Qu N, Buyuksal I, Painter S, Dalton WS: Mutations in the Fas antigen in patients with multiple myeloma. Blood 1997, 90: 4266-4270
10. Grønbæck K, Straten PT, Ralfkiaer E, Ahrenkiel V, Andersen MK, Hansen NE, Zeuthern J, Hou-Jensen K, Guldberg P: Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood 1998, 92:3018-3024
11. Nizas P, Champion AE, Fox M: Germ cell tumors of testis: prognostic factors and results. Eur Urol 1990, 18:242-247
12. Mostofi FK: Comparison of various clinical and pathological classifications of tumors of testes. Semin Oncol 1979, 18:26-30
13. Takayama H, Takakuwa T, Dong Z, Nonomura N, Okuyama A, Nagata S, Aozasa A: Fas gene mutations in prostatic intraepithelial neoplasia and concurrent carcinoma: analysis of laser capture microdissected specimens. Lab Invest 2001, 81:283-288
14. Huang QR, Morris D, Manollos N: Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 1997, 34:577-582
15. Mizushima S, Nagata S: pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Res 1990, 18:5322
16. Itoh N, Yonehara S, Ishii M, Yonehara S, Mizushima M, Sameshima A, Hase A, Seto Y, Nagata S: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991, 66:233-243
17. Lee SH, Shin MS, Park WS, Kim SY, Kim HS, Han JY, Park GY, Dong SM, Pi JH, Kim CH, Kim SH, Lee JY, Yoo NJ: Alterations of Fas (Apo/CD95) gene in non-small cell lung cancer. Oncogene 1999, 18:1754-1760
18. Lee SH, Shin MS, Park WS, Kim SY, Kim HS, Han JY, Park GY, Dong SM, Pi JH, Kim CH, Kim SH, Lee JY, Yoo NJ: Alterations of Fas (Apo/CD95) gene in transitional cell carcinoma of urinary bladder. Cancer Res 1999, 59:3068-3072
19. Takakuwa T, Dong Z, Takayama H, Matsuzuka F, Nagata S, Aozasa A: Frequent mutations of Fas gene in thyroid lymphoma. Cancer Res 2001, 61:1382-1385
20. Huang B, Eberstadt M, Olejniczak ET, Meadows RP, Fesik SW: NMR structure and mutagenesis of the Fas (Apo-1/CD95) death domain. Nature 1996, 384:638-641
21. Straus SE, Jaffe ES, Puck JM, Dale JK, Elkon KB, Rösen-Wolff A, Peters AM, Sneller MC, Hallahan CW, Wang J, Fischer RE, Jackson CM, Lin AY, Baumler C, Siegert E, Marx A, Vaishnaw AK, Grodzicky T, Fleisher TA, Lenardo MJ: The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 2001, 98: 194-200
22. Mostofi FK: Pathology of germ cell tumors of testis: a progress report. Cancer 1980, 45:1735-1754
23. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM: FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995, 81:505-512
24. Boldin MP, Goncharov TM, Goltsev Y, Wallach D: Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1 and TNF receptor induced cell death. Cell 1996, 85:803-815
25. Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH, Wallach D: A novel protein that interacts with the death domain of Fas/Apo 1 contains a sequence motif related to the death domain. J Biol Chem 1995, 270:7795-7798
26. Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz JD, Zhang M, Gentz R, Mann M, Krammer PH, Peter ME, Dixit VM: FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996, 85:817-827
27. Thome M, Schneider P. Hofmann K, Fickenscher H, Meinl E, Neipel F, Mattmann C, Burns K, Bodmer JL, Schroter M, Scaffidi C, Krammer PH, Peter ME, Tschopp J: Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 1997, 386: 517-521